论文部分内容阅读
目的评价卡维地洛治疗慢性心力衰竭的疗效。方法将入选的66例慢性心力衰竭患者随机分为标准治疗组(A组,21例)和卡维地洛组(B组,45例)。B组在A组治疗基础上加用卡维地洛,起始剂量2.5 mg Bid,目标剂量20 mg Bid,治疗4个月,观测治疗前后心率、血压、NYHA心功能分级、12导联心电图、LVEF、LVDD、RVDD、FBG、TG、TC、LDL-C、HDL-C。结果 B组患者治疗后,NYHA心功能分级级数、HR、SBP、DBP、LVDD、RVDD和室早的数量均较治疗前显著降低(P<0.05),LVEF显著增加(P<0.05);与A组患者治疗后相比,NYHA心功能分级级数、HR和室早数量显著减少(P<0.05),LVEF显著增加(P<0.05)。血糖、血脂等指标无明显变化。结论在心衰标准用药基础上给药卡维地洛治疗慢性心衰患者,能显著改善慢性心力衰竭患者的血流动力学状态和临床症状,对临床慢性心力衰竭患者的治疗和生存有重要价值。
Objective To evaluate the efficacy of carvedilol in the treatment of chronic heart failure. Methods Sixty-six patients with chronic heart failure were randomly divided into standard treatment group (group A, n = 21) and carvedilol group (group B, n = 45). In group B, carvedilol was added on the basis of group A, with a starting dose of 2.5 mg bid and a target dose of 20 mg bid for 4 months. The heart rate, blood pressure, NYHA functional classification, 12-lead electrocardiogram, LVEF, LVDD, RVDD, FBG, TG, TC, LDL-C, HDL-C. Results After treatment, the number of NYHA classifications, HR, SBP, DBP, LVDD, RVDD and ventricular volume in patients in group B were significantly lower than those before treatment (P <0.05) Compared with the NYHA group, NYHA classifications of cardiac function, HR and ventricular volume were significantly decreased (P <0.05) and LVEF was significantly increased (P <0.05). Blood glucose, blood lipids and other indicators no significant change. Conclusions The administration of carvedilol to patients with chronic heart failure on the basis of standard medication of heart failure can significantly improve the hemodynamic status and clinical symptoms of patients with chronic heart failure and have important value in the treatment and survival of clinical patients with chronic heart failure .